Henry Schein (NASDAQ:HSIC) Price Target Raised to $87.00 at Wells Fargo & Company

Henry Schein (NASDAQ:HSIC) had its price objective increased by Wells Fargo & Company from $76.00 to $87.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

HSIC has been the topic of several other research reports. JPMorgan Chase & Co. raised their price objective on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Robert W. Baird set a $100.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a report on Monday. Barrington Research set a $79.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Mizuho set a $81.00 price objective on shares of Henry Schein and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Finally, Barclays initiated coverage on shares of Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein Stock Down 1.8%

HSIC stock opened at $81.87 on Wednesday. Henry Schein has a fifty-two week low of $60.56 and a fifty-two week high of $89.29. The company has a market cap of $9.64 billion, a price-to-earnings ratio of 25.04, a P/E/G ratio of 2.48 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.79 and a current ratio of 1.38. The business’s 50-day moving average is $77.66 and its two-hundred day moving average is $71.97.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the prior year, the company earned $1.19 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts forecast that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds have recently made changes to their positions in the company. MAI Capital Management boosted its position in shares of Henry Schein by 7.5% during the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after acquiring an additional 144 shares during the last quarter. CW Advisors LLC lifted its position in Henry Schein by 2.8% during the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after purchasing an additional 163 shares during the last quarter. Truist Financial Corp grew its stake in shares of Henry Schein by 3.3% in the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after buying an additional 175 shares in the last quarter. Simon Quick Advisors LLC increased its stake in Henry Schein by 5.5% during the second quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after acquiring an additional 182 shares during the last quarter. Finally, Claret Asset Management Corp raised its position in Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock valued at $232,000 after purchasing an additional 187 shares during the period. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Company beat Q4 estimates on both EPS and revenue (Q4 EPS $1.34 vs $1.30 est.; revenue $3.44B vs $3.34B) and gave FY‑2026 EPS and revenue guidance roughly in line with consensus — a core driver of the recent rally. Article Title Press Release
• Positive Sentiment: Several brokers raised price targets or upgraded the stock after the earnings beat: JPMorgan to $92 (Overweight), Robert W. Baird upgraded to Outperform with a $100 target, UBS, Mizuho, Wells Fargo and Leerink also lifted targets into the mid‑$80s–$100 range — supporting upside expectations. Benzinga roundup TickerReport
• Positive Sentiment: Market momentum: the shares recently hit a 52‑week high as investors re‑rated growth from equipment, specialty and tech segments after the call. MSN article
• Neutral Sentiment: FY‑2026 guidance was close to Street expectations (EPS 5.23–5.37 vs consensus ~5.28; revenue $13.6–13.8B vs ~$13.5B), which reduces surprise risk but doesn’t materially raise the bar for beat-and-raise momentum. Press Release
• Negative Sentiment: Margin pressures flagged on the call and in analyst notes — revenue growth was strong but margins contracted, which some analysts cite as a reason to temper enthusiasm and cap multiple expansion. Zacks margin note
• Negative Sentiment: Not all analysts turned positive — Morgan Stanley (Erin Wright) maintained a sell/underweight stance with a much lower $58–$61 price target, and some investors may have taken profits or remained cautious because of valuation vs. margin risk. TipRanks Benzinga note

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.